Dr Egan presents 18-month data on use of anti-IL5 therapy in 13 EGPA patients. 50% reduction in steroid dose with anti-IL5. BVAS and asthma control questionnaire improved. 12 of 13 continued anti-IL5. @rheumnow #ACR20 Abstr#1427 https://t.co/qVy7Nb3OoA